Product category:
Clinical chemistry analysis
News Release from: Ipsogen | Subject: NPM1 diagnostics
Edited by the Laboratorytalk Editorial
Team on 18 September 2007
Diagnostic products based on NPM1
mutations
Recent discovery by Falini and Mecucci at Institute of Hematology, University of Perugia, showed that about 60% of adult AML with normal karyotype have a mutation in the nucleophosmin (NPM1) gene
Molecular diagnostic company Ipsogen has signed a co-exclusive license agreement with Xenomics to enable it to develop, manufacture and commercialise research and diagnostic products based on the analysis of NPM1 mutations for the stratification and monitoring of patients with acute myeloid leukemia (AML) AML is a clinically and molecularly heterogeneous disease with about 13,500 new cases per year in the USA and a similar number in Europe
This article was originally published on Laboratorytalk on 22 Nov 2007 at 8.00am (UK)
Related stories
Accurate quantification of Jak2 V617F mutation
Ipsogen has developed a range of molecular assays based on mutations in the Jak2 gene, to which the company has worldwide exclusive intellectual property rights
Pilot study on Jak2 cancer biomarker
Ipsogen has entered into a pilot agreement with AstraZeneca to evaluate molecular services and products in cancer research
The disease subgrouping by cytogenetic karyotyping indicates patient prognosis.
However, in almost half of AML cases the karyotype appears normal.
"This agreement with Xenomics enables Ipsogen to further expand its unique range of diagnostic products dedicated to the disease management of blood cancers" said Vincent Fert, president and CEO of Ipsogen.
"NPM1 products will integrate Ipsogen quantitative and standardised technology (FusionQuant and ProfileQuant) to warrant the highest level of precision and quality for clinical laboratories and patients.
"The NPM1 test results have the potential to help physicians with prognosis of the disease and with the monitoring of the patient response to therapy".
"Xenomics is committed to expanding patient access to the NPM1 marker worldwide," said Samuil Umansky, chief scientific officer of Xenomics.
"With this acute disease, physicians need a rapid assessment of patient prognosis for effective use of chemotherapy.
"NPM1 provides an excellent test for monitoring the minimal residual disease and patients in response to anti-tumour therapy.".
• Ipsogen: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
